<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>D-P-C012-709V</udiDi>
    <basicUdiDi>B-P-C012-709V</basicUdiDi>
    <tradeName>CD4 (QR032)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C012-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.444Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C013-150UN</udiDi>
    <basicUdiDi>B-P-C013-150UN</basicUdiDi>
    <tradeName>CD23 (QR036)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C013-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.419Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C013-309Q</udiDi>
    <basicUdiDi>B-P-C013-309Q</basicUdiDi>
    <tradeName>CD23 (QR036)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C013-30</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.395Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C013-70A4</udiDi>
    <basicUdiDi>B-P-C013-70A4</basicUdiDi>
    <tradeName>CD23 (QR036)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C013-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.379Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C014-150UZ</udiDi>
    <basicUdiDi>B-P-C014-150UZ</basicUdiDi>
    <tradeName>Cytokeratin 7 (QR049)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C014-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.356Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C014-309X</udiDi>
    <basicUdiDi>B-P-C014-309X</basicUdiDi>
    <tradeName>Cytokeratin 7 (QR049)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C014-30</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.246Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C014-70AB</udiDi>
    <basicUdiDi>B-P-C014-70AB</basicUdiDi>
    <tradeName>Cytokeratin 7 (QR049)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C014-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.232Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C015-150VC</udiDi>
    <basicUdiDi>B-P-C015-150VC</basicUdiDi>
    <tradeName>CD20 (QR094)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C015-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.221Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C015-30A6</udiDi>
    <basicUdiDi>B-P-C015-30A6</basicUdiDi>
    <tradeName>CD20 (QR094)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C015-30</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.198Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C015-70AJ</udiDi>
    <basicUdiDi>B-P-C015-70AJ</basicUdiDi>
    <tradeName>CD20 (QR094)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C015-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.173Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C016-150VP</udiDi>
    <basicUdiDi>B-P-C016-150VP</basicUdiDi>
    <tradeName>CDX2 (QR045)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C016-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.156Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C016-30AD</udiDi>
    <basicUdiDi>B-P-C016-30AD</basicUdiDi>
    <tradeName>CDX2 (QR045)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C016-30</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.141Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C016-70AR</udiDi>
    <basicUdiDi>B-P-C016-70AR</basicUdiDi>
    <tradeName>CDX2 (QR045)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C016-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.081Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C017-150W2</udiDi>
    <basicUdiDi>B-P-C017-150W2</basicUdiDi>
    <tradeName>Cytokeratin 5/6 (QR027 &amp; QR028)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C017-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.061Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C017-30AL</udiDi>
    <basicUdiDi>B-P-C017-30AL</basicUdiDi>
    <tradeName>Cytokeratin 5/6 (QR027 &amp; QR028)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C017-30</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.025Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C017-70AY</udiDi>
    <basicUdiDi>B-P-C017-70AY</basicUdiDi>
    <tradeName>Cytokeratin 5/6 (QR027 &amp; QR028)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C017-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:57.014Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C019-150WQ</udiDi>
    <basicUdiDi>B-P-C019-150WQ</basicUdiDi>
    <tradeName>CD34 (QR093)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C019-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:56.999Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C019-30B2</udiDi>
    <basicUdiDi>B-P-C019-30B2</basicUdiDi>
    <tradeName>CD34 (QR093)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C019-30</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:56.975Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C019-70BE</udiDi>
    <basicUdiDi>B-P-C019-70BE</basicUdiDi>
    <tradeName>CD34 (QR093)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C019-70</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:56.954Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-P-C020-150U2</udiDi>
    <basicUdiDi>B-P-C020-150U2</basicUdiDi>
    <tradeName>Chromogranin A</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-C020-150</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T22:56:56.941Z</lastUpdated>
  </row>
</eudamedExport>